Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization

NCT ID: NCT03127722

Last Updated: 2025-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

990 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-03

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to assess post-procedural outcomes for women who chose to undergo either hysteroscopic sterilization (Essure®) or laparoscopic tubal sterilization, including:

* Pelvic and/or lower abdominal pain
* Abnormal uterine bleeding
* Surgical intervention (including "insert removal" and hysterectomy)
* Allergic, hypersensitivity, or autoimmune-like reactions

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contraception

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ESSURE (BAY1454032)

Subjects selecting hysteroscopic sterilization who are not contraindicated for the Essure procedure according to the most current approved version of the Essure IFU. Subject willing to use alternative contraception for at least 3 months post-Essure placement procedure, until a satisfactory Essure Confirmation Test is documented.

Group Type EXPERIMENTAL

Blood draw

Intervention Type PROCEDURE

Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.

ESSURE (BAY1454032)

Intervention Type DEVICE

Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.

Laparoscopic tubal sterilization

Subjects selecting laparoscopic sterilization who are not contraindicated for laparoscopic tubal sterilization according to common clinical practice standard of care

Group Type ACTIVE_COMPARATOR

Blood draw

Intervention Type PROCEDURE

Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.

Laparoscopic tubal sterilization

Intervention Type PROCEDURE

Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood draw

Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.

Intervention Type PROCEDURE

ESSURE (BAY1454032)

Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.

Intervention Type DEVICE

Laparoscopic tubal sterilization

Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who are at least 21 years of age;
* Subjects of all weights will be included;
* Subjects who are scheduled to undergo an Essure insert placement procedure for permanent birth control or laparoscopic tubal sterilization. Decision for either treatment based upon clinical practice and physician/patient counseling.
* For the Essure group only:

• Subjects selecting hysteroscopic sterilization who are not contraindicated for the Essure procedure according to the most current approved version of the Essure IFU;
* For the laparoscopic tubal sterilization group only:

* Subjects selecting laparoscopic sterilization who are not contraindicated for laparoscopic tubal sterilization according to common clinical practice standard of care.

Exclusion Criteria

* Subjects who are post-menopausal;
* Subjects suspected of being or confirmed pregnant;
* Subjects post-partum or undergone pregnancy termination ≤6 weeks prior to scheduled procedure;
* Subjects uncertain about ending fertility;
* Subjects with an active upper or lower genital tract infection;
* Subjects with gynecologic malignancy (suspected or known);
* Subjects who have had an attempted prior sterilization procedure (either laparoscopic or hysteroscopic);
* Subjects scheduled to undergo concomitant intrauterine or laparoscopic procedures at the time of insert placement (intrauterine device removal is not considered a concomitant procedure) or laparoscopic sterilization;
* Subjects with unexplained vaginal bleeding.
Minimum Eligible Age

21 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New Horizons Women's Care

Chandler, Arizona, United States

Site Status

Precision Trials, AZ, LLC

Phoenix, Arizona, United States

Site Status

Visions Clinical Research - Tucson

Tucson, Arizona, United States

Site Status

Eclipse Clinical Research

Tucson, Arizona, United States

Site Status

Baptist Health Center for Clinical Research

Little Rock, Arkansas, United States

Site Status

United Clinical Research

Huntington Beach, California, United States

Site Status

Orange Coast Women's Medical Group - Laguna Hills Office

Laguna Hills, California, United States

Site Status

Physicians Research Options, LLC

Lakewood, Colorado, United States

Site Status

The Women's Health Group, P.C.

Thornton, Colorado, United States

Site Status

M & O Clinical Research, LLC

Fort Lauderdale, Florida, United States

Site Status

Altus Research

Lake Worth, Florida, United States

Site Status

Universal Axon Clinical Research

Miami, Florida, United States

Site Status

Physician Care Clinical Research

Sarasota, Florida, United States

Site Status

Clinical Research Prime, LLLP

Idaho Falls, Idaho, United States

Site Status

John H Stroger Jr. Hospital of Cook County

Chicago, Illinois, United States

Site Status

Women's Health Advantage

Fort Wayne, Indiana, United States

Site Status

IU Health University Hospital

Indianapolis, Indiana, United States

Site Status

Office of Dr. Cindy Basinski, LLC

Newburgh, Indiana, United States

Site Status

Women's Health Care, PC

Newburgh, Indiana, United States

Site Status

The Iowa Clinic, PC

West Des Moines, Iowa, United States

Site Status

University of Kentucky Albert B. Chandler Hospital

Lexington, Kentucky, United States

Site Status

Horizon Research Group of Opelousas, LLC

Eunice, Louisiana, United States

Site Status

Mid-Atlantic Permanente Research Institute

Rockville, Maryland, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

Women's Integrated Health Care, PC

Grand Blanc, Michigan, United States

Site Status

Jersey Shore University Medical Center

Neptune City, New Jersey, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Unified Women's Clinical Research, LLC

Greensboro, North Carolina, United States

Site Status

Women's Health Alliance

Raleigh, North Carolina, United States

Site Status

Unified Women's Clinical Research

Winston-Salem, North Carolina, United States

Site Status

Wake Forest Baptist Health

Winston-Salem, North Carolina, United States

Site Status

Seven Hills Women's Health Centers

Cincinnati, Ohio, United States

Site Status

MetroHealth Medical Center

Cleveland, Ohio, United States

Site Status

Ohio State University

Columbus, Ohio, United States

Site Status

Columbus OB-GYN/Radiant Research

Columbus, Ohio, United States

Site Status

Complete Healthcare for Women, Inc.

Columbus, Ohio, United States

Site Status

Wright State Physicians Health Center

Dayton, Ohio, United States

Site Status

HWC Women's Research Center

Englewood, Ohio, United States

Site Status

HillTop Obstetrics & Gynecology

Franklin, Ohio, United States

Site Status

Amy Brenner, MD & Associates, LLC

Mason, Ohio, United States

Site Status

AC Clinical Research

Tiffin, Ohio, United States

Site Status

Oklahoma University

Oklahoma City, Oklahoma, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

St. Luke's Hospital - Allentown Campus

Allentown, Pennsylvania, United States

Site Status

Women's Health Care Group of PA

Pottstown, Pennsylvania, United States

Site Status

Reading Hospital

West Reading, Pennsylvania, United States

Site Status

Women & Infants Hospital (OGCC)

Providence, Rhode Island, United States

Site Status

Palmetto Clinical Research (PCR)

Charleston, South Carolina, United States

Site Status

OB-GYN Centre of Excellence

Chattanooga, Tennessee, United States

Site Status

University of Tennessee Medical Center

Knoxville, Tennessee, United States

Site Status

Ben Taub General Hospital

Houston, Texas, United States

Site Status

The Woman's Hospital of Texas

Houston, Texas, United States

Site Status

Southeast Texas Family Planning and Cancer Screening

Houston, Texas, United States

Site Status

Brown Stone Clinical Trials, LLC

Irving, Texas, United States

Site Status

Tanner Clinic

Layton, Utah, United States

Site Status

Women's Healthcare Associates, LLC - Tualatin

Pleasant Grove, Utah, United States

Site Status

Tidewater Clinical Research, Inc.

Virginia Beach, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

https://clinicaltrials.bayer.com/study/18894

Click here to find further information and, after study completion, the study results according to Bayer's transparency standards

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18894

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.